Patents by Inventor Volker Schellenberger

Volker Schellenberger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TARGETED XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME
    Publication number: 20180125988
    Abstract: The present disclosure provides drug conjugate compositions, and compositions and methods for preparing and using the same. In some embodiments, the present invention relates to targeted conjugate compositions comprising cysteine-containing domains (CCD) linked to targeting moieties, extended recombinant polypeptides (XTEN)and peptide cleavable moieties, with pharmacologically active payload drugs cross-linked to cysteine residues, resulting in compositions that can be cleaved by proteases associated with target tissues. The invention also provides methods of making the targeted conjugate compositions and methods of using the targeted conjugate compositions.
    Type: Application
    Filed: November 11, 2015
    Publication date: May 10, 2018
    Inventors: Fan YANG, Volker SCHELLENBERGER, Sheng DING, Desiree THAYER, Chia-Wei WANG
  • Biologically active proteins having increased in vivo and/or in vitro stability
    Patent number: 9938331
    Abstract: The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: April 10, 2018
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Willem P. Stemmer, Chia-Wei Wang, Michael D. Scholle, Nathaniel C. Gordon, Andreas Crameri, Mikhail Popkov
  • Extended recombinant polypeptides and compositions comprising same
    Patent number: 9926351
    Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: March 27, 2018
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, Wayne To, Jeffrey L. Cleland
  • TREATMENT WITH HUMAN GROWTH HORMONE ANALOGUES
    Publication number: 20180051063
    Abstract: The present invention concerns an improved therapeutic regimen for GHD therapy. In particular, the invention concerns methods for bolus dose administration of a human growth hormone-XTEN (hGH-XTEN) fusion protein.
    Type: Application
    Filed: July 13, 2017
    Publication date: February 22, 2018
    Inventors: Jeffrey L. Cleland, George M. Bright, Eric Humphriss, Volker Schellenberger, Joshua Silverman, Willem P. Stemmer, Chia-Wei Wang, Nathan Greething, Benjamin Spink
  • Growth hormone polypeptides and methods of making and using same
    Patent number: 9849188
    Abstract: The present invention relates to compositions comprising growth hormone linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of growth hormone-related diseases, disorders, and conditions.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: December 26, 2017
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Joshua Silverman, Willem P. Stemmer, Chia-wei Wang, Nathan Geething, Jeffrey L. Cleland, Benjamin Spink
  • Coagulation factor IX compositions and methods of making and using same
    Patent number: 9758776
    Abstract: The present invention relates to compositions comprising factor IX coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: September 12, 2017
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Willem P. Stemmer, Nathan C. Geething, Wayne To, Joshua Silverman, Chia-wei Wang, Benjamin Spink
  • COAGULATION FACTOR IX COMPOSITIONS AND METHODS OF MAKING AND USING SAME
    Publication number: 20170247676
    Abstract: The present invention relates to compositions comprising factor IX coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions.
    Type: Application
    Filed: February 8, 2017
    Publication date: August 31, 2017
    Applicant: Amunix Operating Inc.
    Inventors: Volker SCHELLENBERGER, Willem P. Stemmer, Nathan C. Geething, Wayne To, Joshua Silverman, Chia-wei Wang, Benjamin Spink
  • BLOOD GLUCOSE LOWERING COMPOUND
    Publication number: 20170240614
    Abstract: The present invention relates to the field of medicine and the treatment of diabetes or hyperglycemia within that field. More particularly, the invention relates to a compound that lowers blood glucose, pharmaceutical compositions containing such a compound, and therapeutic uses of such a compound.
    Type: Application
    Filed: February 16, 2017
    Publication date: August 24, 2017
    Inventors: David Bruce BALDWIN, John Michael BEALS, Andrew Ihor KORYTKO, Bryant Rhodius McLAUGHLIN, Volker SCHELLENBERGER
  • GLUCOSE-REGULATING POLYPEPTIDES AND METHODS OF MAKING AND USING SAME
    Publication number: 20170158748
    Abstract: The present invention relates to compositions comprising glucose regulating peptides linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of glucose regulating peptide-related diseases, disorders, and conditions.
    Type: Application
    Filed: November 30, 2016
    Publication date: June 8, 2017
    Inventors: Volker Schellenberger, Joshua Silverman, Willem P. Stemmer, Chia-wei Wang, Nathan Geething, Jeffrey L. Cleland
  • GROWTH HORMONE POLYPEPTIDES AND METHODS OF MAKING AND USING SAME
    Publication number: 20170095567
    Abstract: The present invention relates to compositions comprising growth hormone linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of growth hormone-related diseases, disorders, and conditions.
    Type: Application
    Filed: September 2, 2015
    Publication date: April 6, 2017
    Inventors: Volker Schellenberger, Joshua Silverman, Willem P. Stemmer, Chia-wei Wang, Nathan Geething, Jeffrey L. Cleland, Benjamin Spink
  • EXTENDED RECOMBINANT POLYPEPTIDES AND COMPOSITIONS COMPRISING SAME
    Publication number: 20170037088
    Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.
    Type: Application
    Filed: May 13, 2016
    Publication date: February 9, 2017
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, Wayne To, Jeffrey L. Cleland
  • BINDING FUSION PROTEINS, BINDING FUSION PROTEIN-DRUG CONJUGATES, XTEN-DRUG CONJUGATES AND METHODS OF MAKING AND USING SAME
    Publication number: 20170016042
    Abstract: The present invention relates to binding fusion protein compositions comprising targeting moieties linked to extended recombinant polypeptide (XTEN), binding fusion protein-drug conjugate compositions, and XTEN-drug conjugate compositions, isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of diseases, disorders, and conditions.
    Type: Application
    Filed: December 21, 2015
    Publication date: January 19, 2017
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P.C. Stemmer, Nathan C. Geething
  • Glucose-regulating polypeptides and methods of making and using same
    Patent number: 9540430
    Abstract: The present invention relates to compositions comprising glucose regulating peptides linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of glucose regulating peptide-related diseases, disorders, and conditions.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: January 10, 2017
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Joshua Silverman, Willem P. Stemmer, Chia-wei Wang, Nathan Geething, Jeffrey L. Cleland
  • FACTOR VIII COMPOSITIONS AND METHODS OF MAKING AND USING SAME
    Publication number: 20160376344
    Abstract: The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.
    Type: Application
    Filed: May 24, 2016
    Publication date: December 29, 2016
    Applicant: Amunix Operating Inc.
    Inventors: Volker SCHELLENBERGER, Pei-Yun CHANG, Fatbardha VARFAJ, John KULMAN, Tongyao LIU, Garabet G. TOBY, Haiyan JIANG, Robert PETERS, Deping WANG, Baisong MEI, Joshua SILVERMAN, Chia-Wei WANG, Benjamin SPINK, Nathan GEETHING
  • COAGULATION FACTOR IX COMPOSITIONS AND METHODS OF MAKING AND USING SAME
    Publication number: 20160362672
    Abstract: The present invention relates to compositions comprising factor IX coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions.
    Type: Application
    Filed: May 24, 2016
    Publication date: December 15, 2016
    Applicant: Amunix Operating Inc.
    Inventors: Volker SCHELLENBERGER, Willem P. Stemmer, Nathan C. Geething, Wayne To, Joshua Silverman, Chia-wei Wang, Benjamin Spink
  • BIOLOGICALLY ACTIVE PROTEINS HAVING INCREASED IN VIVO AND/OR IN VITRO STABILITY
    Publication number: 20160280753
    Abstract: The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.
    Type: Application
    Filed: December 16, 2015
    Publication date: September 29, 2016
    Inventors: Volker Schellenberger, Willem P. Stemmer, Chia-Wei Wang, Michael D. Scholle, Nathaniel C. Gordon, Andreas Crameri, Mikhail Popkov
  • FACTOR VIII-XTEN FUSIONS AND USES THEREOF
    Publication number: 20160199454
    Abstract: The present invention provides chimeric proteins comprising a Factor VIII (FVIII) polypeptide and XTEN polypeptides. The FVIII polypeptide can have a reduced affinity for von Willebrand Factor (VWF). XTEN polypeptides of appropriate sizes are inserted into the FVIII polypeptide at particular locations in order to extend the half-life of the FVIII polypeptide. The invention also includes nucleotides, vectors, host cells, and methods of using the chimeric proteins, e.g., to treat bleeding diseases and disorders.
    Type: Application
    Filed: August 14, 2014
    Publication date: July 14, 2016
    Applicants: Biogen MA Inc., Amunix Operating Inc.
    Inventors: Tongyao LIU, Pei-Yun CHANG, John KULMAN, Volker SCHELLENBERGER, Haiyan JIANG, Robert T. PETERS, Ekta Seth CHHABRA
  • Coagulation factor IX compositions and methods of making and using same
    Patent number: 9376672
    Abstract: The present invention relates to compositions comprising factor IX coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: June 28, 2016
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Willem P. Stemmer, Nathan C. Geething, Wayne To, Joshua Silverman, Chia-wei Wang, Benjamin Spink
  • Extended recombinant polypeptides and compositions comprising same
    Patent number: 9371369
    Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: June 21, 2016
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-Wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, Wayne To, Jeffrey L. Cleland
  • GLUCAGON-LIKE PEPTIDE-2 COMPOSITIONS AND METHODS OF MAKING AND USING SAME
    Publication number: 20160137711
    Abstract: The present invention relates to compositions comprising GLP-2 protein or variants thereof linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in the treatment of GLP-2-related conditions.
    Type: Application
    Filed: September 12, 2012
    Publication date: May 19, 2016
    Applicant: AMUNIX OPERATING INC.
    Inventors: Volker Schellenberger, Joshua Silverman, Willem P. Stemmer, Chia-Wei Wang, Nathan Geething, Benjamin Spink